Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340336 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340415 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340350 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340417 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340147 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340096 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13339763 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340405 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13339809 | 1.00 | MAPT (0.32) | MAPTESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL13340206 | 0.97 | MAPT (0.33) | MAPTESR1ESR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-05-06 | — | — | US | disclosed |
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OR10J3, OCIAD1, OCIAD2 | MAPT 3478/4885ESR1 221/4885ESR2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.